Non-Transfusion-dependent Alpha-ThalassemiaPhase 3ENERGIZEKidsNCT07517133
A Study to Investigate the Efficacy, Pharmacokinetics, and Safety of Mitapivat in Pediatric Participants With α- or β-Non-Transfusion-Dependent Thalassemia
A Phase 3 study testing Mitapivat in people with Non-Transfusion-dependent Alpha-Thalassemia and Non-Transfusion-dependent Beta-Thalassemia, run by Agios Pharmaceuticals, Inc. at 5 sites in United States.
Trial summary
The primary objective of this study is to compare the effect of mitapivat versus placebo on anemia in pediatric participants with alpha- or beta-non-transfusion-dependent thalassemia. Read more about this study
- Who is it for?
- Ages 1 year to 17 years
- Conditions the study is for
- Non-Transfusion-dependent Alpha-Thalassemia, Non-Transfusion-dependent Beta-Thalassemia
- What is being tested?
- Mitapivat
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 45 participants
- Where
- 5 sitesUnited States
- Study dates
- Sep 2026to Mar 2032
- Phase
- Phase 3
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 1 year to 17 years
- All sexes
- No healthy volunteers
- Child
Who may be able to join
- Written informed consent/assent from the participant (or their legally authorized representative, parent(s), or legal guardian) must be obtained before any study-related procedures are conducted and participants must be willing to comply with all study procedures for the duration of the study.
- Aged 1 to <18 years and weighing at least 7 kilograms (kg) at the time of providing informed consent/assent.
- Documented diagnosis of thalassemia (β-thalassemia with or without α-globin gene mutations, hemoglobin E (HbE)/β-thalassemia, or α-thalassemia/hemoglobin H (HbH) disease) based on Hemoglobin (Hb) electrophoresis, Hb high-performance liquid chromatography, and/or DNA analysis from the participant's medical record. If this information is not available from the participant's medical record, the test(s) can be performed by a local laboratory during the Screening Period. If a local laboratory is unable to perform the test(s), results from the comprehensive α- and β-globin genotyping performed by the study central laboratory can be used.
- Hb concentration ≤10.0 grams per deciliter (g/dL) [100.0 grams per liter (g/L)], based on an average of at least 2 Hb concentration measurements (separated by ≥7 days) collected during the Screening Period.
- Non-transfusion dependent, defined as ≤5 transfusion episodes (also referred to as "transfusion events") during the 24-week period before randomization and no red blood cells (RBC) transfusions ≤8 weeks before providing informed consent/assent and no RBC transfusions during the Screening Period.
- If taking hydroxyurea, the hydroxyurea dose must be stable for ≥16 weeks before randomization.
- Female participants who have attained menarche must be abstinent of sexual activities that may induce pregnancy as part of their usual lifestyle, or agree to use 2 forms of contraception, 1 of which must be considered highly effective, from the time of informed consent/assent, throughout the study, and for 28 days after the last dose of study drug. The second form of contraception can include an acceptable barrier method.
Who cannot join
- Pregnant or breastfeeding.
- Documented history of homozygous or heterozygous hemoglobin S (HbS) or hemoglobin C (HbC).
- Prior exposure to gene therapy or prior bone marrow or stem cell transplantation, including any prior exposure to myeloablative chemotherapy.
- Any conditions other than thalassemia expected to affect sexual maturation.
- Currently receiving treatment with luspatercept; the last dose must have been administered ≥18 weeks before randomization.
- Currently receiving treatment with hematopoietic stimulating agents; the last dose must have been administered ≥18 weeks before randomization.
Show all 26Show fewer
- History of malignancy (active or treated) ≤5 years before providing informed consent/assent, except for nonmelanomatous skin cancer in situ, cervical carcinoma in situ, or breast carcinoma in situ.
- History of active and/or uncontrolled cardiac or pulmonary disease or clinically relevant QT prolongation within 6 months before providing informed consent/assent.
- Hepatobiliary disorders, including but not limited to:
- Liver disease with histopathological evidence or clinical diagnosis of cirrhosis or severe fibrosis.
- Clinically symptomatic cholelithiasis or cholecystitis (prior cholecystectomy is not exclusionary).
- History of drug-induced cholestatic hepatitis.
- Aspartate Aminotransferase (AST) >2.5*Upper Limit of Normal (ULN) (unless due to hemolysis and hepatic iron deposition) and Alanine Transaminase (ALT) >2.5*ULN (unless due to hepatic iron deposition).
- Renal dysfunction as defined by an estimated glomerular filtration rate <60 milliliters per minute (mL/min)/1.73-meter square (m^2).
- Nonfasting triglycerides >215 milligrams per deciliter (mg/dL) [5 millimole per liter (mmol/L)].
- Active infection requiring systemic antimicrobial therapy at the time of providing informed consent/assent. If antimicrobial therapy is required during the Screening Period, screening procedures should not be performed while antimicrobial therapy is being administered, and the last dose of antimicrobial therapy must be administered ≥7 days before randomization.
- Participants with known active hepatitis B or hepatitis C virus infection.
- Participants with known human immunodeficiency virus (HIV) infection.
- History of major surgery (including splenectomy) ≤16 weeks before providing informed consent/assent and/or a major surgical procedure planned during the study.
- Current enrollment or past participation (within ≤12 weeks or a timeframe equivalent to 5 half-lives of the investigational study drug before administration of the first dose of study drug, whichever is longer) in any other clinical study involving an investigational treatment or device.
- Receiving strong Cytochrome3A4/5 (CYP3A4/5) inhibitors that have not been stopped for ≥5 days or a timeframe equivalent to 5 half-lives (whichever is longer), or strong CYP3A4/5 inducers that have not been stopped for ≥4 weeks or a timeframe equivalent to 5 half-lives (whichever is longer), before randomization.
- Receiving anabolic steroids that have not been stopped for at least 4 weeks before randomization. Testosterone replacement therapy to treat hypogonadism is allowed; the testosterone dose and preparation must be stable for ≥12 weeks before randomization.
- Known allergy, or other contraindication, to mitapivat or its excipients (microcrystalline cellulose, croscarmellose sodium, sodium stearyl fumarate, mannitol, magnesium stearate, and the Opadry filmcoat [hypromellose, titanium dioxide, lactose monohydrate triacetin, and FD\&C Blue #2]).
- Any medical, hematological, psychological, or behavioral condition(s) or prior or current therapy that, in the opinion of the Investigator, may confer an unacceptable risk to participating in the study and/or could confound the interpretation of the study data. Also excluded are:
- Participants who are institutionalized by regulatory or court order.
- Participants with any condition(s) that could create undue influence (including but not limited to incarceration, involuntary psychiatric confinement, and financial or familial affiliation with the Investigator or Sponsor).
Trial locations and contacts
5 sites in 1 country. Contact the study team or a site near you to ask about taking part.
5 sites in 1 country
United States5 sites, 5 recruiting
- Recruiting
Emory-Children's Center/ Children's Healthcare of Atlanta: Arthur M. Blank Hospital
Atlanta, Georgia, 30322
- Recruiting
University of Texas Southwestern Medical Center
Dallas, Texas, 75390
- Recruiting
Weill Cornell Medical College/ New York Presbyterian
New York, New York, 10065
- Recruiting
Stanford Medicine
Palo Alto, California, 94304
- Recruiting
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, 19104-4318
About this study
Official title: A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Efficacy, Pharmacokinetics, and Safety of Mitapivat in Pediatric Subjects With α- or β-Non-Transfusion-Dependent Thalassemia
The primary objective of this study is to compare the effect of mitapivat versus placebo on anemia in pediatric participants with alpha- or beta-non-transfusion-dependent thalassemia.
- Being tested
- Mitapivat, Placebo Matching Mitapivat
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
MitapivatDrug
Also called AG-348, Mitapivat sulfate
Tablets or Granules
Placebo Matching MitapivatDrug
Tablets or Granules
| Study group | Role | What they receive |
|---|---|---|
| Mitapivat | Experimental | Participants will receive oral mitapivat twice daily (BID), with the dose determined by age and weight, for 24 weeks during the double blind (DB) period. Enrollment is conducted sequentially by age cohort, beginning with the oldest cohort.
Cohort 1: 12 to <18 years
Cohort 2: 6 to <12 years
Cohort 3: 1 to <6 years
Participants who complete the DB period may continue receiving mitapivat in the open label extension (OLE) period for up to 144 weeks. Receives: Drug: Mitapivat |
| Placebo | Placebo comparator | Participants will receive oral placebo matching mitapivat, administered BID, with dosing based on age and weight, for 24 weeks during the DB period. Enrollment is conducted sequentially by age cohort, beginning with the oldest cohort.
Cohort 1: 12 to <18 years
Cohort 2: 6 to <12 years
Cohort 3: 1 to <6 years
Participants who complete the DB period may transition to receive mitapivat in the OLE period for up to 144 weeks. Receives: Drug: Placebo Matching Mitapivat |
What is being measured
The primary outcome is the main question the study is designed to answer.
Percentage of Participants Who Achieved a Hemoglobin (Hb) Response
Hb response is defined as a ≥1.0 grams per deciliter (g/dL) increase in average Hb concentration from Week 12 through Week 24 compared with baseline.
Measured: Baseline, Week 12 through Week 24
Secondary outcomes (28)
Change From Baseline in Average Hb Concentration From Week 12 Through Week 24
Measured: Baseline, Week 12 through Week 24
Percentage of Participants Who Achieved a Hb 1.5+ Response
Hb 1.5+ response is defined as a ≥1.5 g/dL increase in average Hb concentration from Week 12 through Week 24 compared with Baseline.
Measured: Baseline, Week 12 through Week 24
Change From Baseline in Indirect Bilirubin at Week 24
Measured: Baseline, Week 24
Change From Baseline in Lactate Dehydrogenase (LDH) at Week 24
Measured: Baseline, Week 24
Change From Baseline in Haptoglobin at Week 24
Measured: Baseline, Week 24
Change From Baseline in Reticulocytes at Week 24
Measured: Baseline, Week 24
Change From Baseline in Erythropoietin at Week 24
Measured: Baseline, Week 24
Cohort 1: Change From Baseline in Estradiol Through Week 24
Measured: Baseline, up to Week 24
Cohort 1: Change From Baseline in Estrone Through Week 24
Measured: Baseline, up to Week 24
Cohort 1: Change From Baseline in Total Testosterone Through Week 24
Measured: Baseline, through Week 24
Cohort 1: Change From Baseline in Free Testosterone Through Week 24
Measured: Baseline, through Week 24
Cohort 1: Change From Baseline in Luteinizing Hormone Through Week 24
Measured: Baseline, through Week 24
Cohort 1: Change From Baseline in Sexual Maturity Rating With Tanner Stage Through Week 24
Measured: Baseline, through Week 24
Cohort 1: Percentage of Female Participants With Newly Developed Ovarian Cysts Through Week 24
Measured: Baseline, through Week 24
Change From Baseline Over Time in Height-for-age Z-Score, Weight-for-age Z-Score, and Body Mass Index (BMI)-for-age Z-Score Through Week 24
Measured: Baseline, through Week 24
Change from Baseline in Bone Mineral Density (BMD) Through Week 24
Measured: Baseline, through Week 24
Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
Measured: From first dose of the study drug to the end of DB period (through Week 24)
Change from Baseline Through Week 24 in Pediatric Quality of Life (PedsQL) Multidimensional Fatigue Scale
The PedsQL Multidimensional Fatigue Scale measures dimensions of fatigue over a 7-day recall period. It includes 3 subscales: general fatigue, sleep/rest fatigue, and cognitive fatigue. Items are reverse-scored and linearly transformed to a 0-100 scale so that higher PedsQL Multidimensional Fatigue Scale scores indicate better health-related quality of life (HRQOL) (fewer symptoms of fatigue).
Measured: Baseline, through Week 24
Change from Baseline Through Week 24 in PedsQL 4.0 Generic Core Scale (GCS)
HRQOL will be assessed using the PedsQL Multidimensional 4.0 Generic Core Scales (for participants 2 years or older). The PedsQL 4.0 Generic Core Scales are multidimensional, well-validated measures of quality of life in childhood. They each consist of 4 subscales: physical health, emotional functioning, social functioning, and school functioning are reverse-scored and linearly transformed to a 0-100 scale, with higher scores indicating better HRQOL.
Measured: Baseline, through Week 24
Change From Baseline in Serum Iron at Week 24
Measured: Baseline, Week 24
Change From Baseline in Total Iron-binding Capacity at Week 24
Measured: Baseline, Week 24
Change From Baseline in Transferrin at Week 24
Measured: Baseline, Week 24
Change From Baseline in Transferrin Saturation at Week 24
Measured: Baseline, Week 24
Change From Baseline in Serum Ferritin at Week 24
Measured: Baseline, Week 24
Plasma Concentration of Mitapivat
Measured: Pre-dose and at multiple timepoints post-dose (up to 7 hours post-dose) at Week 4
Area Under the Plasma Concentration-Time Curve From Time Zero to Last Quantifiable Concentration (AUC0-last) of Mitapivat
Measured: Pre-dose and at multiple timepoints post-dose (up to 7 hours post-dose) at Week 4
Maximum Observed Plasma Concentration (Cmax) of Mitapivat
Measured: Pre-dose and at multiple timepoints post-dose (up to 7 hours post-dose) at Week 4
Time to Reach Maximum Observed Plasma Concentration (Tmax) of Mitapivat
Measured: Pre-dose and at multiple timepoints post-dose (up to 7 hours post-dose) at Week 4
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted8 Apr 2026
- Study startSep 2026 (estimated)
- Primary completionMar 2029 (estimated)
- Study completionMar 2032 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Non-Transfusion-dependent Alpha-ThalassemiaStudies of the same condition, open and under way.
- More trials run by Agios Pharmaceuticals, Inc.The sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 45 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Agios Pharmaceuticals, Inc.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07517133
- Sponsor's protocol ID
- AG348-C-028
- Other IDs
- 2025-524706-15-00, 2025
- Acronym
- ENERGIZEKids
- Status last verified
- Oct 2026
- First submitted
- 26 Mar 2026
- Last updated
- 28 Oct 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 28 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Efficacy, Pharmacokinetics, and Safety of Mitapivat in Pediatric Subjects With α- or β-Non-Transfusion-Dependent Thalassemia
- ClinicalTrials.gov ID
- NCT07517133
- Acronym / sponsor ID
- ENERGIZEKids / AG348-C-028
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 45 participants (estimated)
- Lead sponsor
- Agios Pharmaceuticals, Inc.Industry (pharma, biotech, devices)
- Study start
- Sep 2026 (estimated)
- Primary completion
- Mar 2029 (estimated)
- Study completion
- Mar 2032 (estimated)
- First posted
- 8 Apr 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The primary objective of this study is to compare the effect of mitapivat versus placebo on anemia in pediatric participants with alpha- or beta-non-transfusion-dependent thalassemia.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Mitapivat | Experimental | Drug: MitapivatParticipants will receive oral mitapivat twice daily (BID), with the dose determined by age and weight, for 24 weeks during the double blind (DB) period. Enrollment is conducted sequentially by age cohort, beginning with the oldest cohort. Cohort 1: 12 to <18 years Cohort 2: 6 to <12 years Cohort 3: 1 to <6 years Participants who complete the DB period may continue receiving mitapivat in the open label extension (OLE) period for up to 144 weeks. |
| Placebo | Placebo comparator | Drug: Placebo Matching MitapivatParticipants will receive oral placebo matching mitapivat, administered BID, with dosing based on age and weight, for 24 weeks during the DB period. Enrollment is conducted sequentially by age cohort, beginning with the oldest cohort. Cohort 1: 12 to <18 years Cohort 2: 6 to <12 years Cohort 3: 1 to <6 years Participants who complete the DB period may transition to receive mitapivat in the OLE period for up to 144 weeks. |
Who may qualify
- Ages
- 1 year to 17 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child
Key inclusion criteria (7 listed)
- Written informed consent/assent from the participant (or their legally authorized representative, parent(s), or legal guardian) must be obtained before any study-related procedures are conducted and participants must be willing to comply with all study procedures for the duration of the study.
- Aged 1 to <18 years and weighing at least 7 kilograms (kg) at the time of providing informed consent/assent.
- Documented diagnosis of thalassemia (β-thalassemia with or without α-globin gene mutations, hemoglobin E (HbE)/β-thalassemia, or α-thalassemia/hemoglobin H (HbH) disease) based on Hemoglobin (Hb) electrophoresis, Hb high-performance liquid chromatography, and/or DNA analysis from the participant's medical record. If this information is not available from the participant's medical record, the test(s) can be performed by a local laboratory during the Screening Period. If a local laboratory is unable to perform the test(s), results from the comprehensive α- and β-globin genotyping performed by the study central laboratory can be used.
- Hb concentration ≤10.0 grams per deciliter (g/dL) [100.0 grams per liter (g/L)], based on an average of at least 2 Hb concentration measurements (separated by ≥7 days) collected during the Screening Period.
- Non-transfusion dependent, defined as ≤5 transfusion episodes (also referred to as "transfusion events") during the 24-week period before randomization and no red blood cells (RBC) transfusions ≤8 weeks before providing informed consent/assent and no RBC transfusions during the Screening Period.
Key exclusion criteria (26 listed)
- Pregnant or breastfeeding.
- Documented history of homozygous or heterozygous hemoglobin S (HbS) or hemoglobin C (HbC).
- Prior exposure to gene therapy or prior bone marrow or stem cell transplantation, including any prior exposure to myeloablative chemotherapy.
- Any conditions other than thalassemia expected to affect sexual maturation.
- Currently receiving treatment with luspatercept; the last dose must have been administered ≥18 weeks before randomization.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| MitapivatAlso: AG-348, Mitapivat sulfateTablets or Granules | Drug | Mitapivat |
| Placebo Matching MitapivatTablets or Granules | Drug | Placebo |
Primary outcome
Percentage of Participants Who Achieved a Hemoglobin (Hb) Response
Time frame: Baseline, Week 12 through Week 24
Hb response is defined as a ≥1.0 grams per deciliter (g/dL) increase in average Hb concentration from Week 12 through Week 24 compared with baseline.
28 secondary outcomes
Change From Baseline in Average Hb Concentration From Week 12 Through Week 24
Time frame: Baseline, Week 12 through Week 24
Percentage of Participants Who Achieved a Hb 1.5+ Response
Time frame: Baseline, Week 12 through Week 24
Change From Baseline in Indirect Bilirubin at Week 24
Time frame: Baseline, Week 24
Change From Baseline in Lactate Dehydrogenase (LDH) at Week 24
Time frame: Baseline, Week 24
Change From Baseline in Haptoglobin at Week 24
Time frame: Baseline, Week 24
Change From Baseline in Reticulocytes at Week 24
Time frame: Baseline, Week 24
Change From Baseline in Erythropoietin at Week 24
Time frame: Baseline, Week 24
Cohort 1: Change From Baseline in Estradiol Through Week 24
Time frame: Baseline, up to Week 24
Cohort 1: Change From Baseline in Estrone Through Week 24
Time frame: Baseline, up to Week 24
Cohort 1: Change From Baseline in Total Testosterone Through Week 24
Time frame: Baseline, through Week 24
Cohort 1: Change From Baseline in Free Testosterone Through Week 24
Time frame: Baseline, through Week 24
Cohort 1: Change From Baseline in Luteinizing Hormone Through Week 24
Time frame: Baseline, through Week 24
Cohort 1: Change From Baseline in Sexual Maturity Rating With Tanner Stage Through Week 24
Time frame: Baseline, through Week 24
Cohort 1: Percentage of Female Participants With Newly Developed Ovarian Cysts Through Week 24
Time frame: Baseline, through Week 24
Change From Baseline Over Time in Height-for-age Z-Score, Weight-for-age Z-Score, and Body Mass Index (BMI)-for-age Z-Score Through Week 24
Time frame: Baseline, through Week 24
Change from Baseline in Bone Mineral Density (BMD) Through Week 24
Time frame: Baseline, through Week 24
Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
Time frame: From first dose of the study drug to the end of DB period (through Week 24)
Change from Baseline Through Week 24 in Pediatric Quality of Life (PedsQL) Multidimensional Fatigue Scale
Time frame: Baseline, through Week 24
Change from Baseline Through Week 24 in PedsQL 4.0 Generic Core Scale (GCS)
Time frame: Baseline, through Week 24
Change From Baseline in Serum Iron at Week 24
Time frame: Baseline, Week 24
Change From Baseline in Total Iron-binding Capacity at Week 24
Time frame: Baseline, Week 24
Change From Baseline in Transferrin at Week 24
Time frame: Baseline, Week 24
Change From Baseline in Transferrin Saturation at Week 24
Time frame: Baseline, Week 24
Change From Baseline in Serum Ferritin at Week 24
Time frame: Baseline, Week 24
Plasma Concentration of Mitapivat
Time frame: Pre-dose and at multiple timepoints post-dose (up to 7 hours post-dose) at Week 4
Area Under the Plasma Concentration-Time Curve From Time Zero to Last Quantifiable Concentration (AUC0-last) of Mitapivat
Time frame: Pre-dose and at multiple timepoints post-dose (up to 7 hours post-dose) at Week 4
Maximum Observed Plasma Concentration (Cmax) of Mitapivat
Time frame: Pre-dose and at multiple timepoints post-dose (up to 7 hours post-dose) at Week 4
Time to Reach Maximum Observed Plasma Concentration (Tmax) of Mitapivat
Time frame: Pre-dose and at multiple timepoints post-dose (up to 7 hours post-dose) at Week 4
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 28 Oct 2026.
- Individual participant dataSharing planned: No
Related trials for Non-Transfusion-dependent Alpha-Thalassemia
Active, not recruitingPhase 3
A Study Evaluating the Efficacy and Safety of Mitapivat in Participants With Non-Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-NTDT)
Non-Transfusion-dependent Alpha-Thalassemia, Non-Transfusion-dependent Beta-Thalassemia
Active, not recruitingPhase 2
A Study to Determine the Efficacy and Safety of Luspatercept in Adult Participants and to Evaluate the Safety and Pharmacokinetics in and Adolescent Participants With Alpha (α)-Thalassemia
Anemia
RecruitingPhase 2
Reduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT
Primary Immunodeficiency (PID), Congenital Bone Marrow Failure Syndromes
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
5 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing Mitapivat in people with Non-Transfusion-dependent Alpha-Thalassemia and Non-Transfusion-dependent Beta-Thalassemia, run by Agios Pharmaceuticals, Inc. at 5 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 26 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 28 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 5 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Agios Medical Affairs (833-228-8474, medinfo@agios.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Percentage of Participants Who Achieved a Hemoglobin (Hb) Response (time frame: Baseline, Week 12 through Week 24). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Oct 2026.